Efficacy and Safety of Endostar^®Combined with Chemotherapy in Patients with Advanced Soft Tissue Sarcomas

Abstract

Background: Soft tissue sarcomas (STS) are a heterogeneous group of tumors, and approximately 40-50% of patients with STS develop metastatic disease. The median overall survival of those patients was 12 months and their 5-year survival rate was 8%. Therefore, study on more effective treatment, especially the targeting therapies, is urgently needed. Objective: To evaluate the efficacy and safety of Endostar® combined with chemotherapy in patients with advanced STS. Methods: A retrospective case-series study was conducted in Cancer Institute of PLA, Xinqiao Hospital. A total of 71 patients suffering from advanced STS (IIB -IV) were included, of whom 49 cases treated with chemotherapy alone were defined as the control group and the rest 22 cases treated with the traditional chemotherapy combined with Endostar® were defined as the test group. The short-term therapeutic effects including objective response rate (ORR), disease control rate (DCR) and safety were evaluated in the two groups. In the follow-up, progression-free survival (PFS) and overall survival (OS) were also observed. Results: In the test and control groups, the ORR was 18.2% and 12.2%, respectively (P = 0.767), and the DCR was 86.4% and 61.2%, respectively (P=0.034). The median time to progression in the test and control groups was 120 days and 70 days with significant difference (P = 0.017), while the median overall survival was 452 days and 286 days without significant difference (P = 0.503). The one-year survival rate in the test group and control group was 56.2% and 35.4%, respectively, while the two-year survival rate was 30.2% and 26.5%, respectively. No significant difference in the side effects was found between the two groups. Conclusions: Endostar® combined with chemotherapy resulted in a higher DCR and longer PFS in the patients with advanced STS, and the toxicity was tolerable.

Computed Tomography Manifestations of Histologic Subtypes of Retroperitoneal Liposarcoma

“…To compare the safety and efficacy of chemotherapy in patients with STS, Cao et al demonstrates that epirubicin-based chemotherapy is effective and well tolerated and Kaya et al suggests that the combination of gemcitabine plus docetaxel is an active and tolerable regimen as a second line therapy (Kaya et al, 2012;Cao et al, 2013). Endostar combined with chemotherapy resulted in a higher disease control rate and longer progression-free survival (Zhang et al, 2013). In the study of Asia-Pacific region, specialists suggest RPLS be multi-disciplinarily managed with a team involving pathologists, radiologists, surgeons, radiation therapists and medical oncologists because of the different histotypes, sites, and disease stages assessed (Duman et al, 2012).…”

Current Status and Study Progress of Recombinant Human Endostatin in Cancer Treatment

“…Zhang et al [57] explored the clinical efficacy of rh-endostatin combined with chemotherapy in the treatment of advanced soft-tissue sarcoma. The control group received conventional chemotherapy.…”

Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV

“…Endostar, is a novel recombinant human endostatin, with advantages of long half-life, stable and low cost [16]. Recently, a study of Endostar combined with chemotherapy in the treatment of advanced soft tissue sarcoma indicated resulted in a higher clinical benefit response (CBR) and longer progression-free survival (PFS), with tolerable side effects [17]. However this study included the patients with stage ΠB-IV soft tissue sarcomas and did not include specific pathologic information.…”